$1.17
▼ -4.9% Today
as of Oct 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
CLRB earnings at a glance
Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±8.3% on average; after the most recent report on May 14, 2026 it moved +8.8%. CLRB beat the consensus EPS estimate in 4 of its last 4 reported quarters. The share price of $1.17 sits near its 52-week low.
Overview
52-week range
$1.12
$4.70
1% of range
Avg surprise (last 4)
+14.3%
Avg reaction (last 2)
+0.6%
50% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.57 | — | — | — | — | financials |
| Thu May 14, 2026 | Mar/2026 | $-1.33 | $-1.35 | +1.5% | -923.1% | +8.8% | earnings |
| Thu Nov 13, 2025 | Sep/2025 | $-1.41 | $-1.91 | +26.2% | — | — | earnings |
| Thu Aug 14, 2025 | Jun/2025 | $-3.39 | $-3.60 | +5.8% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.13 | $-0.17 | +23.5% | — | -7.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-12.13 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-5.43 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.91 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.55 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-7M | $-6M | — | $-5M | $-6M | $-6M | — | $-13M |
| Net income | $-7M | $-6M | — | $-4M | $-5M | $-7M | — | $-15M |
| EPS (diluted) | $-0.57 | $-1.33 | — | $-1.41 | $-3.39 | $-4.30 | — | $-12.13 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $34M | $8M | $13M | $13M | $11M | $14M | $23M | $34M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $35M | $9M | $14M | $14M | $13M | $15M | $24M | $36M |
| Total assets | $37M | $11M | $15M | $15M | $14M | $16M | $25M | $37M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $7M | $6M | $5M | $5M | $6M | $6M | $10M | $21M |
| Total equity | $30M | $3M | $9M | $8M | $6M | $8M | $14M | $15M |
Implied volatility — last 90 days
No IV snapshots yet for CLRB.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.
Sector peers
CLRB earnings FAQ
How does CLRB stock usually react to earnings?
Across the last 2 reports the average next-day move was ±8.3%, up 1 times and down 1 times.